

June 12, 2012

Hisamitsu Pharmaceutical Co.,Inc.
sanofi-aventis K.K.

Establishment of Joint Venture for OTC Allergy Medications

Sanofi-aventis K.K. (Head Office: Shinjuku-ku, Tokyo; President: Jez Moulding; hereafter "saKK") and Hisamitsu Pharmaceutical Co.,Inc. (Head Office: Tosu-shi, Saga; President: Hirotaka Nakatomi; hereafter "Hisamitsu") announced today that they signed an agreement to establish a joint venture for over-the-counter (OTC) allergy medications business in Japan as follows.

Company name	SANOFI-HISAMITSU K.K.
Headquarters	Tokyo Opera City Tower, 3-20-2, Nishi Shinjuku, Shinjuku-ku, Tokyo
Representative	Jez Moulding, Representative Director - President & Chairman
Date of establishment	July 2, 2012 (planned)
Capital	250 million JPY
Capital contribution ratio	sanofi-aventis K.K. : 51% Hisamitsu Pharmaceutical Co.,Inc. : 49%
Business activity	Marketing of OTC allergy medications

SaKK is a Sanofi company, which is a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Consumer healthcare business is one of its seven growth platforms of the Group. In Japan, saKK has contributed to patients' treatment through providing innovative ethical pharmaceuticals.

Hisamitsu has committed to people's health since its establishment in 1847, by providing medical supplies centered on antiphlogistic analgesic adhesive skin patches. In the field of OTC drug, the company has rich sales know-how and marketing capability, which have fostered its brands including Salonpas® products.

Leveraging each strength through the new joint venture, the two companies aim to contribute to self-medication in Japan by Hisamitsu's selling OTC allergy medications, of which sanofi-aventis will be the marketing authorization holder (MAH).